Hypothesis: HLA-DQA1*05 plus methotrexate dose and early trough kinetics will outperform biologic class alone for predicting anti-drug antibodies in autoimmune therapy

Claim
In autoimmune patients treated with adalimumab or infliximab, a model that combines HLA-DQA1*05 carriage, methotrexate dose adequacy, and early drug trough kinetics will predict anti-drug antibody formation more accurately than biologic class alone.
Why this matters
Anti-drug antibodies are a major reason for secondary loss of response, but current bedside risk assessment still overweights biologic class and underweights the interaction between host genetics and immunomodulator co-therapy. If the hypothesis is true, it would justify earlier therapeutic drug monitoring and more deliberate methotrexate optimization.
Mechanistic rationale
- HLA-DQA1*05 increases susceptibility to immunogenicity against anti-TNF biologics.
- Methotrexate reduces immunogenicity in a dose-dependent manner, likely by dampening the adaptive immune response and improving drug persistence.
- Early trough kinetics should capture the biologically relevant consequence of emerging antibodies before overt clinical failure.
Testable prediction
In a prospective autoimmune cohort starting anti-TNF therapy:
- A multivariable model with HLA-DQA1*05, methotrexate dose, and week-4/week-12 trough levels will show materially better discrimination for anti-drug antibody formation than biologic class alone.
- The largest effect will be in adalimumab and infliximab users without adequate methotrexate co-therapy.
- The model will remain predictive after adjustment for disease duration, baseline CRP, smoking, and prior biologic failure.
Proposed study
- Population: adults with RA, SpA, or psoriatic disease starting adalimumab or infliximab
- Exposure: HLA-DQA1*05, methotrexate dose, smoking, CRP, prior biologic failure
- Outcome: confirmed anti-drug antibodies with loss of response or dose escalation by 6 months
- Analysis: AUROC comparison, calibration slope, decision-curve analysis, and prespecified net reclassification improvement
Falsifiability
This hypothesis fails if adding genotype, methotrexate dose, and early trough kinetics does not improve discrimination, calibration, or clinical net benefit over biologic class alone.
References
- Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology. 2020;158(1):189-199.e5. DOI: 10.1053/j.gastro.2019.09.041
- Krieckaert CLM, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914-1915. DOI: 10.1136/annrheumdis-2012-201544
- Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021;17(2):81-97. DOI: 10.1038/s41584-020-00540-8